Aster DM Healthcare reports solid Q3 FY26 growth, combined proforma revenue up 15%
On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr
On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr
The viewer aims to help radiologists work smarter, faster, and more collaboratively, while reducing IT complexity and freeing up valuable clinical time
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
This will be Aster’s fifth hospital in Bengaluru
The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow
The merged entity ‘Aster DM Quality Care’ will be jointly controlled by Aster Promoters and Blackstone
The new lenders – JP Morgan, HSBC, and Barclays provided fresh funding
Aster commits to increase bed capacity in the State via capacity expansion and greenfield projects
Subscribe To Our Newsletter & Stay Updated